Dyadic International, a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, has announced that it has been issued US Patent No. 8,268,585 entitled, “Transformation System in the Field of Filamentous Fungal Hosts” by the United States Patent and Trademark Office.
Dyadic‘s President and CEO, Mark Emalfarb, stated, “We are very excited to have been granted this new US patent containing such broad and encompassing claims that provide additional protection for the C1 fungal expression system for Dyadic, its customers and licensees.”
The inventions embodied by this patent describe methods of developing, programming and growing improved strains of the fungal microorganisms which make up Dyadic’s C1 platform technology. The patent claims cover the construction and use of C1 strains for the economical over-production of enzymes and other proteins at industrial scale for a broad number of applications such as food, animal feed, fuels and pharmaceuticals as well as primary and secondary metabolites such as organic acids and antibiotics.
Several of the issued patent claims relate to commercially advantageous properties of improved C1 strains which grow under low viscosity conditions and produce the targeted enzyme or other protein in a cleaner background which enhances the quality, quantity and cost-effectiveness of the final products. The patent also covers several molecular tools such as promoters and vectors which are integral to the process of gene expression resulting in higher productivity levels of enzymes and other proteins.
This patent is the eleventh US patent issued to Dyadic adding to its portfolio of 58 international patents, 38 pending international and 13 pending US patent applications which cover various features of Dyadic’s proprietary technologies.
2/3 articles remaining | Register to continue reading.